Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells

Journal of Immunotherapy

Volumn 34, Issue 2, 2011, Pages 187-195

  Zhang, Hua ^a   Cui, Yongzhi ^a   Voong, Nga ^a   Sabatino, Marianna ^b   Stroncek, Dave F ^b   Morisot, Sebastien ^c   Civin, Curt I ^c   Wayne, Alan S ^a   Levine, Bruce L ^d   MacKall, Crystal L ^a,e  

^a NCI   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Pediatric Oncology Branch   (United States)

Author keywords

activating NK receptor; cytotoxicity; killer cell immunoglobulin like receptor; natural killer cells

Indexed keywords

CD137 LIGAND; INTERLEUKIN 15 RECEPTOR ALPHA; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; RECOMBINANT INTERLEUKIN 15; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOLYSIS; DRUG TARGETING; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TUMOR CELL DESTRUCTION;

4-1BB LIGAND; ANIMALS; ANTIGEN-PRESENTING CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTERLEUKIN-15; INTERLEUKIN-15 RECEPTOR ALPHA SUBUNIT; K562 CELLS; KILLER CELLS, NATURAL; MICE; RECEPTORS, KIR; RECEPTORS, NATURAL CYTOTOXICITY TRIGGERING; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 79953062729     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31820d2a21     Document Type: Article

References (44)

1. Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol. 2008;9:503-510. (Pubitemid 351560519)
2. Karre K, Ljunggren HG, Piontek G, et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319:675-678. (Pubitemid 16119452)
3. Moretta L, Bottino C, Pende D, et al. Surface NK receptors and their ligands on tumor cells. Semin Immunol. 2006;18:151-158. (Pubitemid 43817561)
4. Hamerman JA, Ogasawara K, Lanier LL. NK cells in innate immunity. Curr Opin Immunol. 2005;17:29-35. (Pubitemid 40094010)
5. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23: 225-274. (Pubitemid 40563170)
6. Kumar V, McNerney ME. A new self: MHC-class-I-indepen-dent natural-killer-cell self-tolerance. Nat Rev Immunol. 2005; 5:363-374. (Pubitemid 40685986)
7. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333-339. (Pubitemid 29300166)
8. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100. (Pubitemid 34229476)
9. Miller JS, Cooley S, Parham P, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007;109:5058-5061. (Pubitemid 46827806)
10. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004; 172:644-650. (Pubitemid 38020523)
11. Binyamin L, Alpaugh RK, Hughes TL, et al. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol. 2008;180:6392-6401.
12. Koh CY, Ortaldo JR, Blazar BR, et al. NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade. Blood. 2003;102:4067-4075. (Pubitemid 37486990)
13. Koh CY, Blazar BR, George T, et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood. 2001;97:3132-3137.
14. Venstrom JM, Zheng J, Noor N, et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res. 2009;15: 7330-7334.
15. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science. 2000;290:84-89.
16. Stern N, Markel G, Arnon TI, et al. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol. 2005;174:6692-6701. (Pubitemid 40705631)
17. Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA. 2009;106: 17858-17863.
18. Cantoni C, Bottino C, Augugliaro R, et al. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur J Immunol. 1999;29: 3148-3159. (Pubitemid 29484205)
19. Fernandez NC, Treiner E, Vance RE, et al. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood. 2005;105: 4416-4423. (Pubitemid 40720789)
20. Shi J, Tricot G, Szmania S, et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008;143:641-653.
21. Cantoni C, Bottino C, Vitale M, et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med. 1999;189:787-796.
22. Pogge von Strandmann E, Simhadri VR, von Tresckow B, et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity. 2007;27:965-974. (Pubitemid 350251218)
23. Brandt CS, Baratin M, Yi EC, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 2009;206:1495-1503.
24. Gonzalez S, Lopez-Soto A, Suarez-Alvarez B, et al. NKG2D ligands: key targets of the immune response. Trends Immunol. 2008;29:397-403.
25. Pessino A, Sivori S, Bottino C, et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med. 1998;188:953-960. (Pubitemid 28433421)
26. Lundqvist A, Yokoyama H, Smith A, et al. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood. 2009;113:6120-6127.
27. Anfossi N, Andre P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25:331-342. (Pubitemid 44224147)
28. Caligiuri MA. Human natural killer cells. Blood. 2008;112:461-469.
29. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106:376-383. (Pubitemid 40967217)
30. Yu J, Heller G, Chewning J, et al. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol. 2007;179:5977-5989.
31. Ferlazzo G, Tsang ML, Moretta L, et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med. 2002;195:343-351. (Pubitemid 34461492)
32. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA. 2001;98:11521-11526. (Pubitemid 32928761)
33. Diefenbach A, Jensen ER, Jamieson AM, et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413:165-171. (Pubitemid 32867877)
34. Zhang H, Snyder KM, Suhoski MM, et al. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol. 2007;179:4910-4918.
35. Suhoski MM, Golovina TN, Aqui NA, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther. 2007;15:981-988. (Pubitemid 46621657)
36. Grimm EA, Mazumder A, Zhang HZ, et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823-1841. (Pubitemid 12074218)
37. Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69:4010-4017.
38. Markel G, Seidman R, Besser MJ, et al. Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells. PLoS One. 2009;4:e5597.
39. Vales-Gomez M, Reyburn HT, Erskine RA, et al. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/ NKG2-C to HLA-E. EMBO J. 1999;18:4250-4260. (Pubitemid 29364127)
40. Vales-Gomez M, Reyburn HT, Erskine RA, et al. Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc Natl Acad Sci USA. 1998;95: 14326-14331. (Pubitemid 28549366)
41. Kulkarni S, Martin MP, Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin Immunol. 2008;20:343-352.
42. Bakker AB, Wu J, Phillips JH, et al. NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Hum Immunol. 2000;61:18-27. (Pubitemid 30058763)
43. Baessler T, Charton JE, Schmiedel BJ, et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood. 2009;115:3058-3069.
44. Cho D, Shook DR, Shimasaki N, et al. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 2010;16:3901-3909.